Abstract 334P
Background
Compared to global figures, breast cancer mortality to incidence ratio is worst in Sub Saharan Africa where about 80% of patients present with locally advanced and metastatic disease at diagnosis. In Cameroon, breast cancer is the commonest cancer with 4,170 cases recorded each year constituting 20.1% of all cancers diagnosed. Late disease presentation is attributed to poor awareness, absence of organized early detection programs, and inadequate facilities for accurate and timely diagnosis and treatment. Our objective was to investigate the role that nurses involved in cervical cancer screening/prevention can play in early detection of breast cancer in Cameroon.
Methods
The nurses involved in cervical cancer screening/prevention in a large faith-based healthcare organization called the Cameroon Baptist Convention Health Services (CBCHS) were trained to do clinical breast exams (CBE) for women aged 21 years and over, and also trained on breast tissue collection for pathology processing and examination. Clients with abnormal breast findings were provided Fine Needle Aspirations (FNA), TruCut biopsies or referred for ultrasound and/or mammography depending on the clinical presentation.
Results
Between January 2020 and December 2022, a total of 16,038 women age range (14-99) years were provided CBE with a mean and median age of 40.4 and 39, respectively. Among these, 750 (4.7%) had abnormal findings. Among those with abnormal findings, 397(52.9%) had breast masses for which 213 (53.7%) had TruCut biopsies and FNA and the others were either referred or had previously established diagnosis. From the 213 Tru-Cut biopsies and FNA’s done, 76 (35.7%) showed a pathology diagnosis of invasive breast cancer while the others showed: acute mastitis 3 (2.9%), fibroadenoma 25 (11.7%), benign mass 83 (39.0%), non-diagnostic 12 (5.6%) and other diagnosis 19 (8.9%).
Conclusions
Nurses can play a key role in early detection of breast cancer if they are trained, and this can greatly reduce the number of women seen with late stage disease and also reduce mortality rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
252P - Adjuvant chemotherapy in T1a/bN0 breast cancer patients with high oncotype DX recurrence scores (RS>25)
Presenter: Daniela Katz
Session: Poster session 02
253P - Is 6-weekly administration of pembrolizumab in combination with chemotherapy for early triple-negative breast cancer safe? A real-world early comparison of q6w versus q3w administration of pembrolizumab in two large cancer centres in the UK
Presenter: Vasileios Angelis
Session: Poster session 02
254P - Effects of delaying adjuvant chemotherapy initiation on clinical outcomes in early triple-negative breast cancer patients
Presenter: Maria Eleni Hatzipanagiotou
Session: Poster session 02
255P - Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 02
256P - Evolution and risk stratification of adjuvant treatment strategies for early breast cancer: A Chinese perspective based on a national cancer database
Presenter: Ying Fan
Session: Poster session 02
257P - The characteristics of HER2-positive microinvasive breast cancer and the necessity of chemotherapy and anti-HER2 therapy in these patients: A real-world study
Presenter: Bo Lan
Session: Poster session 02
258P - Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for high-risk early-stage triple-negative breast cancer in Colombia
Presenter: Ricardo Brugés Maya
Session: Poster session 02
259P - Adjuvant doxorubicin-cyclophosphamide in early-stage breast cancer provides long-term cardiac safety
Presenter: Thiti Susiriwatananont
Session: Poster session 02
260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy
Presenter: Hee Jun Choi
Session: Poster session 02
261P - Dysregulation of immune checkpoint proteins in newly- diagnosed early breast cancer patients undergoing neoadjuvant chemotherapy: A comparison between TNBC and non-TNBC patients
Presenter: Bernardo Rapoport
Session: Poster session 02